Brief: Bio-Rad Q3 Adjusted EPS USD 2.26 Vs. IBES Estimate USD 1.95
29/10/2025 20:15
Oct 29 (Reuters) - Bio-Rad Q3 gross margin 52.6%. Q3 net income USD -341.9 million Q3 sales USD 653 million vs. IBES estimate USD 651.8 million Q3 EPS USD -12.7 outlook FY adjusted revenue growth 0-1%
Recent news on Bio-Rad Laboratories
See all newsUS RESEARCH ROUNDUP-Cencora, Dave, Uber
Bio-Rad Laboratories, Inc. reports results for the quarter ended September 30 - Earnings Summary
Bio-Rad's Q3 revenue comes slightly above estimates on Clinical Diagnostics growth
Brief: Bio-Rad Q3 EBIT Margin -7.6%
Bio-Rad Laboratories, Inc. reports results for the quarter ended June 30 - Earnings Summary